J Mueller-Brand
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab
Forrer F, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A. Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab. Q J Nucl Med Mol Imaging 2012; 56:544-50.
01.12.2012Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab
01.12.2012Q J Nucl Med Mol Imaging 2012; 56:544-50
Forrer Flavio, Oechslin-Oberholzer C, Campana B, Maecke H, Mueller-Brand J, Lohri A
Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma
Forrer F, Riedweg I, Maecke H, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008; 52:334-40.
16.05.2008Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma
16.05.2008Q J Nucl Med Mol Imaging 2008; 52:334-40
Forrer Flavio, Riedweg I, Maecke H R, Mueller-Brand J
Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours
Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2005; 32:511-2; author reply 513.
01.04.2005Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours
01.04.2005Eur J Nucl Med Mol Imaging 2005; 32:511-2; author reply 513
Forrer Flavio, Mueller-Brand J, Maecke H
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
Forrer F, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke H. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31:1257-62.
10.06.2004A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
10.06.2004Eur J Nucl Med Mol Imaging 2004; 31:1257-62
Forrer Flavio, Uusijärvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke H R